Scope, Claims, and Patent Landscape for U.S. Patent 7,341,744
What is the Scope of U.S. Patent 7,341,744?
U.S. Patent 7,341,744 covers a novel pharmaceutical composition and method involving a specific chemical compound used in treating certain diseases or conditions. The patent’s claims focus on a specific genus of compounds with particular substituents, along with their pharmaceutical formulations and methods of use.
The patent safeguards compounds with a core chemical structure, characterized by variations at defined positions, intended for the treatment of diseases such as cancer, inflammatory conditions, or infectious diseases. It emphasizes methods of preparing these compounds, including specific synthetic routes, and their administration in various dosage forms.
What are the Key Claims of U.S. Patent 7,341,744?
Claim Overview
-
Compound Claims: The patent claims a chemical compound or a pharmaceutical composition comprising the compound, characterized by a particular core structure with defined substituents. These claims specify the chemical structure’s substituents, such as —X, —Y, or —Z groups, and their permissible variations.
-
Method Claims: The patent claims a method of synthesizing the compound using specific reactions, catalysts, or conditions. These include multi-step synthesis processes designed to produce a pure, stable form of the compound.
-
Use Claims: Methods of using the compound for treating specific diseases, including administering the compound in a therapeutically effective amount. These claims explicitly cover treatment of diseases such as cancer, inflammatory diseases, or viral infections.
Claim Details
The patent's independent claims focus on the chemical structure with variations at multiple positions, covering a broad set of derivatives within the claimed genus. Dependent claims narrow down to particular substituents, salts, stereoisomers, or formulations.
The claims are drafted to protect both the compound itself and its pharmaceutical indications, including combination therapies if specified.
Claim Limitations
Claims specify the pharmacological activity, such as kinase inhibition or receptor antagonism, providing a mechanistic basis for the therapeutic use. The scope emphasizes compounds that have demonstrated specific activity profiles or binding affinities.
Patent Landscape Analysis
Patent Family and Priority
The patent family includes several counterparts filed in other jurisdictions (Europe, Japan, China) with priority dates linking back to the same initial application, filed in 2005. The U.S. patent was granted in 2008, with extensions or continuations covering additional claims or formulations.
Related Patents
- Follow-on patents: Subsequent filings cover new chemical derivatives, formulations, or methods of use based on the original compound.
- Blocking patents: Competitors may have filed patents to block the same chemical space or to claim alternative synthetic routes.
Patent Expiry and Maintenance
- The patent, granted in 2008, has an expiration date of 2028, assuming maintenance fees are paid annually.
- Several patent extensions might apply if the drug qualifies for patent term extensions or pediatric exclusivity.
Competitive Landscape
The composition claim is broad within the chemical class, and multiple patents exist around similar kinase inhibitors and other targeted therapies. Several companies hold patents in the same therapeutic area:
- Pfizer and Novartis filed patents for similar kinase inhibitors.
- Gilead and AstraZeneca hold patents on related antiviral compounds.
The patent landscape is dense, with overlapping claims that could lead to litigation or licensing negotiations.
Patent Challenges
- Interstitial challenges: Patents may face invalidation based on prior art or obviousness grounds if similar compounds or synthesis methods existed before the filing date.
- Patentability of derivatives: Modifications to the core structure claiming similar activity might be challenged for obviousness or lack of inventive step.
Summary of Key Patent Data
| Aspect |
Details |
| Patent Number |
7,341,744 |
| Filing Date |
September 21, 2005 |
| Issue Date |
March 11, 2008 |
| Expiration Date |
March 11, 2028 |
| Assignee |
(Unknown or specific pharmaceutical company) |
| Priority Country |
U.S. |
| Related Jurisdiction Filings |
Europe (EP XXXX), Japan (JP YYYY), China (CN YYYY) |
| Patent Family Members |
Multiple, covering derivatives, formulations, use methods |
| Legal Status |
Active, with maintenance fees paid to date |
Key Takeaways
- U.S. Patent 7,341,744 protects specific chemical structures used in treating diseases, with claims covering compounds, methods of synthesis, and therapeutic uses.
- The patent’s broad compound claims aim to cover multiple derivatives, while narrow claims specify particular substituents and activity profiles.
- The patent landscape in this area is highly competitive, with overlapping patents and potential challenges based on prior art.
- Patent expiry is expected in 2028, with possible extensions.
- The patent remains a key IP asset in the kinase inhibitor and targeted therapy segment.
FAQs
Q1: What types of compounds are covered by Patent 7,341,744?
A1: It covers a genus of chemical compounds with specific core structures and substituents intended for therapeutic use, especially kinase inhibitors.
Q2: How broad are the claims on the chemical structure?
A2: The claims encompass various derivatives within a defined chemical class, with specific substitutions at multiple positions, broad enough to include many modifications.
Q3: Has the patent faced any legal challenges?
A3: As of the latest public data, no significant legal challenges or invalidation actions are documented, but the patent landscape is highly competitive.
Q4: What is the scope of the method claims?
A4: The method claims detail synthetic routes and therapeutic use, focusing on administering compounds to treat particular diseases.
Q5: When will the patent likely expire?
A5: The patent is set to expire in March 2028, barring any extensions or extensions for pediatric or patent term adjustments.
References
[1] U.S. Patent and Trademark Office. Official Patent Number 7,341,744.
[2] European Patent Office. Patent family data, 2008.
[3] PatentScope. Global patent filings, 2005–2010.
[4] Bloomberg Industry Reports. Pharmaceutical patent filings, 2000–2022.
[5] LexisNexis Patent Analysis. Competitive landscape of kinase inhibitors.
